2238 Moussouttas, Michael M - Jefferson Medical College - Thomas Jefferson University
Michael M. Moussouttas, MD

Michael M. Moussouttas, MD

Contact Dr. Moussouttas

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-1234
(215) 923-6792 fax

Most Recent Peer-reviewed Publications

  1. Prevalence, timing, risk factors, and mechanisms of anterior cerebral artery infarctions following subarachnoid hemorrhage
  2. Impact of acute lung injury and acute respiratory distress syndrome after traumatic brain injury in the United States
  3. Posterior reversible encephalopathy syndrome presenting as opsoclonus-myoclonus
  4. Determinants of central sympathetic activation in spontaneous primary subarachnoid hemorrhage.
  5. Determinants of Central Sympathetic Activation in Spontaneous Primary Subarachnoid Hemorrhage
  6. Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage
  7. Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage
  8. CSF catecholamine profile in subarachnoid hemorrhage patients with neurogenic cardiomyopathy
  9. Impact of intraventricular hemorrhage upon intracerebral hematoma expansion
  10. Perioperative stroke after total joint arthroplasty: Prevalence, predictors, and outcome
  11. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage
  12. Thunderclap headache with normal CT and lumbar puncture: Further investigations are unnecessary: Against
  13. Emerging therapies: ESPRIT
  14. Cerebrovascular disease among patients from the Indian subcontinent
  15. Analysis of the Endothelial Nitric Oxide Synthase Gene as a Modifier of the Cerebral Response to Ischemia
  16. Eclamptic subarachnoid haemorrhage without hypertension
  17. Metabolic syndrome: contributing factors and treatment strategies.
  18. Amnestic syndrome of the subcallosal artery: A novel infarct syndrome
  19. Emerging therapies: Clopidogrel and aspirin [4]
  20. Combination antiplatelet agents in ischemic cerebrovascular disease
0